Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Abiraterone Acetate
Related studies linked through entity extraction aliases.
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Status
- RECRUITING
- Phase
- N/A
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Status
- RECRUITING
- Phase
- PHASE2
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Status
- RECRUITING
- Phase
- PHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2